Related Experiment Video
Updated: Jun 8, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Characterization and clinical outcomes of drug-eluting in-stent restenosis
Hana Vaknin-Assa1, Abid Assali, Eli Lev
1Cardiac Catheterization Laboratories, Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Background:
The best therapeutic alternative for patients suffering from in-stent restenosis after drug-eluting stent implantation remains to be elucidated.
Objective:
To characterize the pattern, treatment and outcomes of DES-related in-stent restenosis in patients treated at our institution.
Methods:
We determined the incidence and major adverse clinical events in 71 consecutive patients with DES failure among 2473 patients who were treated with 2548 drug-eluting stents between 2004 and 2007. We analyzed the clinical data, procedural parameters and clinical outcomes.
Results:
The type and number of stents implanted were as follows: Cypher (n = 1808), Endeavor (421) and Taxus (319); of these, 53 (2.9%), 10 (2.4%), and 8 (2.5%) patients respectively presented with restenosis. The mean time to restenosis was 11.3 +/- 9.9 months. Patients' mean age was 65 +/- 11 years; 75% were male, and 68% had diabetes mellitus. Unstable angina was the clinical presentation in 52 (73%). At 6 months, 3 patients had developed myocardial infarction (4.2%), repeat restenosis at follow-up was diagnosed in 8 patients (11.3%), the overall major adverse clinical events rate was 18.3% (13 patients), and 2 patients died (2.8%).
Conclusions:
Drug-eluting stent-related restenosis is relatively infrequent but remains a clinical challenge. It occurs more frequently in complex lesion subsets, but the overall intermediate-term prognosis is tolerable.
